BVF Partners OS Ltd. 4
Accession 0000921895-16-006424
Filed
Dec 29, 7:00 PM ET
Accepted
Dec 30, 5:37 PM ET
Size
23.8 KB
Accession
0000921895-16-006424
Insider Transaction Report
- Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total
- Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total
- Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total
- Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total
- Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total
- Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total
- Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+260,046$347,317→ 2,334,644 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+77,076$102,943→ 698,623 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+2,348$3,145→ 3,629,958 total - Purchase
Common Stock, $0.001 par value
2016-12-28$1.34/sh+401,726$536,545→ 3,627,610 total - Purchase
Common Stock, $0.001 par value
2016-12-30$1.34/sh+1,205$1,614→ 2,335,849 total
Footnotes (4)
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Documents
Issuer
INFINITY PHARMACEUTICALS, INC.
CIK 0001113148
Related Parties
1- filerCIK 0001660684
Filing Metadata
- Form type
- 4
- Filed
- Dec 29, 7:00 PM ET
- Accepted
- Dec 30, 5:37 PM ET
- Size
- 23.8 KB